Business Wire
22 Sept 2026, 12:50 UTC · 1h ago
Verdict
Headline takes no side. We score MLCO +0.80 across one claim — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
The More Life Company reported that an exploratory eight-participant study showed rapid systemic appearance of USP testosterone using Quicksome™ sublingual delivery.
Newannounced in press release dated 2026-09-22
So whatSuccessful proof-of-concept for sublingual delivery could significantly shorten the R&D timeline for a commercial testosterone product by FY2027.
More positive than 92% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 84% of ticker scores this week
The company announced successful results from a human pharmacokinetic study for its patented delivery technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+3.3%
Price agrees with the score
$4.88 vs $4.72 close before publication (Sep 21) · not market-adjusted
MLCO chart →